# FDA Expands Casgevy CRISPR Gene Therapy Approval to Children Aged Two and Older

> fda · REPORTED · 2026-07-06

The FDA expanded approval of Vertex Pharmaceuticals' Casgevy (exagamglogene autotemcel), the world's first CRISPR gene therapy, to patients aged two years and older with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia. This label extension significantly broadens the eligible patient population for the landmark CRISPR-based treatment.

About Vertex Pharmaceuticals / Casgevy: Vertex Pharmaceuticals is a global biotechnology company focused on serious diseases including cystic fibrosis, sickle cell disease, and kidney disease, with Casgevy being its co-developed CRISPR-based gene editing therapy for hemoglobinopathies developed with CRISPR Therapeutics.

- Company: Vertex Pharmaceuticals / Casgevy
- Sector: therapeutics
- Primary source: https://realeconomy.rsmus.com/5-things-to-know-in-life-sciences-week-of-july-6-2026/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.